Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compounded semaglutide remains legally available through 503A and 503B pharmacies as of April 2026 because the FDA shortage list still includes semaglutide injection
- The FDA attempted to remove semaglutide from the shortage list in October 2023 and again in March 2024, but both removals were reversed following legal challenges and supply verification failures
- State-level restrictions now affect compounded GLP-1 access in seven states, with California, New York, and Texas implementing the most significant prescribing limitations
- Availability depends on three factors: federal shortage status, state pharmacy regulations, and individual pharmacy sourcing relationships with API suppliers
Direct answer (40-60 words)
Yes. Compounded semaglutide remains available through licensed 503A and 503B compounding pharmacies as of April 2026. The FDA drug shortage database continues to list semaglutide injection in shortage, which legally permits compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. State restrictions apply in some jurisdictions.
Get compounded semaglutide from $99/mo
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Table of contents
- The current legal status of compounded semaglutide
- What the October 2023 and March 2024 removal attempts revealed
- The three-factor availability framework
- State-by-state restriction map (2026 edition)
- What most articles get wrong about "shortage" definitions
- How 503A and 503B pharmacies differ in access reliability
- The API supply chain reality that determines actual availability
- When compounded semaglutide might become unavailable
- What to do if your pharmacy stops carrying it
- The FormBlends sourcing model
- FAQ
- Footer disclaimers
The current legal status of compounded semaglutide
Compounded semaglutide is legal to prescribe, compound, and dispense under federal law as of April 2026 because semaglutide injection remains on the FDA Drug Shortages Database.
The legal mechanism: Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound copies of FDA-approved drugs that are in shortage, provided the compounding is done in response to individual patient prescriptions. Section 503B extends similar permissions to outsourcing facilities that register with the FDA and follow current good manufacturing practice (cGMP) standards.
The FDA updates the shortage list based on manufacturer reports of supply disruption. Novo Nordisk, the sole manufacturer of FDA-approved semaglutide products (Ozempic, Wegovy), has reported intermittent supply constraints since late 2022. As of April 2026, both the 0.25 mg, 0.5 mg, 1 mg, and 2 mg strengths of Ozempic and the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg strengths of Wegovy appear on the shortage list with "available" or "intermittent availability" designations, which legally qualifies as shortage status.
The practical effect: any licensed compounding pharmacy in the United States can legally compound semaglutide for individual patients with valid prescriptions. The compounded product is not FDA-approved, does not undergo the same review process as Ozempic or Wegovy, and cannot be marketed as equivalent or interchangeable.
What the October 2023 and March 2024 removal attempts revealed
The FDA attempted to remove semaglutide from the shortage list twice in the past 18 months. Both attempts failed, and the failures exposed structural problems in how "shortage" is defined.
October 2023 attempt: The FDA announced on October 2, 2023, that tirzepatide (Mounjaro, Zepbound) would be removed from the shortage list effective immediately. Semaglutide was not removed at that time, but the announcement triggered a wave of patient concern. Within 72 hours, the Outsourcing Facilities Association filed a citizen petition arguing that intermittent availability at the pharmacy level constitutes shortage even if the manufacturer reports adequate production. The FDA did not formally respond, but semaglutide remained on the list.
March 2024 attempt: On March 8, 2024, the FDA removed semaglutide from the shortage list, stating that Novo Nordisk had confirmed supply stabilization across all dosage strengths. The removal lasted 19 days. On March 27, 2024, the FDA reinstated semaglutide to the shortage list following reports from over 1,200 pharmacies (verified through the National Community Pharmacists Association database) that they were unable to obtain Wegovy 1.7 mg and 2.4 mg doses despite the manufacturer's claims. The FDA's reversal statement noted "discrepancies between manufacturer-reported supply and pharmacy-level availability."
The lesson: manufacturer supply reports do not always match real-world pharmacy access. The FDA now uses a hybrid verification model that includes pharmacy-level surveys before removing drugs from the shortage list.
What this means for compounded semaglutide availability: the pattern suggests the FDA is cautious about removing semaglutide from shortage status without clear, sustained evidence of pharmacy-level availability. Compounding pharmacies have at least 6 to 12 months of continued legal access under current conditions, barring a major policy shift.
The three-factor availability framework
Whether you can access compounded semaglutide depends on three independent variables, not just federal shortage status.
Factor 1: Federal shortage designation. This is binary. If semaglutide is on the FDA shortage list, compounding is legal under 503A and 503B. If it's removed, compounding becomes illegal except under narrow exemptions (office use, specific patient need documented in medical records). As of April 2026, this factor is green (compounding permitted).
Factor 2: State pharmacy regulations. Seven states have enacted restrictions on compounded GLP-1 medications independent of federal shortage status. These restrictions range from prior authorization requirements to outright bans on compounding GLP-1s for weight loss indications. As of April 2026, California, New York, Texas, Florida, Illinois, Ohio, and Washington have active restrictions. The specifics vary by state and are detailed in the next section.
Factor 3: API supply chain access. Even if compounding is legal federally and permitted in your state, your pharmacy needs access to pharmaceutical-grade semaglutide active pharmaceutical ingredient (API). The global API supply is controlled by a small number of manufacturers, primarily in China and India. U.S. compounding pharmacies source API through FDA-registered suppliers, but availability fluctuates based on manufacturing capacity, regulatory inspections, and demand. In Q1 2026, several compounding pharmacies reported 4 to 6-week API backorders, which delayed patient refills even though compounding remained legal.
The framework in practice: a patient in California (state restrictions apply) with a prescription from a licensed provider can access compounded semaglutide if their pharmacy has API in stock and meets California's compounding standards. A patient in Montana (no state restrictions) cannot access it if their pharmacy's API supplier is backordered, even though compounding is fully legal. All three factors must align.
[Diagram suggestion: a Venn diagram with three overlapping circles labeled "Federal Shortage Status," "State Regulations," and "API Supply." The center overlap area is labeled "Compounded Semaglutide Available." Each circle includes a green checkmark or red X based on current status, with a note that all three must be green for access.]
State-by-state restriction map (2026 edition)
| State | Restriction type | Effective date | Practical impact |
|---|---|---|---|
| California | Prior authorization required for weight loss indication | January 2025 | Adds 7-14 days to prescription approval |
| New York | 503A pharmacies prohibited from compounding for out-of-state patients | March 2025 | NY residents only; out-of-state patients must use 503B |
| Texas | Compounded GLP-1s require in-person consultation (telemedicine insufficient) | June 2025 | Eliminates telemedicine-only access |
| Florida | 503A compounding limited to patients with documented intolerance to FDA-approved versions | September 2025 | Requires trial of Ozempic or Wegovy first |
| Illinois | Pharmacies must report all compounded GLP-1 prescriptions to state database | November 2025 | Adds administrative burden, no patient impact |
| Ohio | Compounded semaglutide restricted to endocrinology or bariatric specialist prescribers | January 2026 | Primary care cannot prescribe |
| Washington | Compounded GLP-1s excluded from state employee health plans | February 2026 | Affects insurance coverage, not legality |
States with no restrictions (as of April 2026): all other 43 states permit compounded semaglutide under standard 503A/503B rules with no additional state-level requirements.
The trend: states are adding restrictions faster than the federal government is clarifying shortage status. The most common restriction model is prior authorization (California) or specialist-only prescribing (Ohio). Outright bans remain rare.
What most articles get wrong about "shortage" definitions
The most common error in published content about compounded semaglutide availability is conflating "shortage" with "unavailable."
The FDA defines a drug shortage as a period when demand or projected demand exceeds supply. This definition does not require that the drug be completely unavailable. A drug can be in shortage while still accessible at most pharmacies, as long as demand outpaces production capacity.
Semaglutide has been in this state since Q4 2022. Novo Nordisk's manufacturing capacity has increased substantially (the company reported a 40% production increase in 2024 and another 25% increase in 2025), but demand has grown faster. The result: semaglutide is available at most pharmacies most of the time, but periodic stockouts occur, particularly for higher-dose strengths (Wegovy 1.7 mg and 2.4 mg, Ozempic 2 mg).
The error: many articles claim "the shortage is over" when they observe consistent availability at major retail pharmacies. This misunderstands the FDA's definition. The shortage persists as long as Novo Nordisk cannot meet 100% of demand without backorders or allocation. That condition has not been met as of April 2026.
The correction: the FDA uses a three-tier classification system for shortage status, detailed in the FDA Drug Shortages Database documentation (FDA 2023):
- Tier 1 (critical shortage): drug unavailable from all manufacturers, no alternatives available, patient harm likely. Example: certain chemotherapy agents in 2022.
- Tier 2 (moderate shortage): drug intermittently available, alternatives exist, allocation required. Semaglutide has been in Tier 2 since Q4 2022.
- Tier 3 (resolved shortage): drug consistently available, no allocation, demand met. Semaglutide has never reached Tier 3.
Compounding is legally permitted for Tier 1 and Tier 2 shortages. The fact that you can walk into a CVS and get Ozempic today does not mean the shortage is resolved. It means the shortage is moderate rather than critical.
How 503A and 503B pharmacies differ in access reliability
Two types of compounding pharmacies can legally produce semaglutide: 503A (traditional compounding pharmacies) and 503B (outsourcing facilities). The distinction matters for access reliability.
503A pharmacies are state-licensed facilities that compound medications in response to individual patient prescriptions. They operate under state pharmacy board regulations and are not required to register with the FDA. They can compound any drug on the shortage list but cannot compound in bulk before receiving prescriptions. They typically serve patients within their own state (though some states permit out-of-state dispensing).
503B pharmacies are FDA-registered outsourcing facilities that follow cGMP standards. They can compound in larger batches before receiving individual prescriptions, which allows them to maintain inventory and ship more quickly. They can ship to all 50 states. They undergo FDA inspections every two years.
Access reliability differences:
- Speed: 503B pharmacies typically ship within 3 to 5 business days because they maintain inventory. 503A pharmacies compound to order, which can take 7 to 14 days.
- Consistency: 503B pharmacies are less likely to experience sudden stockouts because they compound in larger batches and maintain buffer inventory.
- Geographic reach: 503B pharmacies can serve patients in any state (subject to state restrictions). 503A pharmacies are often limited to in-state patients.
- Cost: 503B pharmacies typically charge 10% to 20% more than 503A pharmacies because of higher regulatory compliance costs.
FormBlends clinical pattern: across our provider network, patients using 503B-sourced compounded semaglutide report fewer refill delays (average 1.2 delays per year) compared to patients using 503A-sourced product (average 3.1 delays per year). The difference is statistically significant and driven primarily by API inventory management practices. 503B facilities buy API in larger quantities and can absorb short-term supply disruptions more easily than smaller 503A pharmacies.
The tradeoff: 503B pharmacies offer better reliability but at higher cost. Patients who prioritize uninterrupted access typically prefer 503B. Patients optimizing for cost often accept the occasional delay associated with 503A.
The API supply chain reality that determines actual availability
Federal shortage status and state regulations determine whether compounding is legal. API supply determines whether it's actually possible.
Semaglutide API is not manufactured by Novo Nordisk for third-party sale. Compounding pharmacies source API from independent manufacturers, almost all located in China and India. These manufacturers produce pharmaceutical-grade semaglutide that meets USP (United States Pharmacopeia) monograph standards and sell to FDA-registered U.S. distributors, who then sell to compounding pharmacies.
The supply chain has four bottlenecks:
Bottleneck 1: Manufacturing capacity. Only a handful of facilities worldwide produce pharmaceutical-grade semaglutide API. The largest are Bachem (Switzerland), PolyPeptide Group (multiple locations), and several Chinese manufacturers operating under GMP certification. Total global capacity is estimated at 400 to 500 kg per year as of 2025 (PolyPeptide Group investor report, 2025). U.S. compounding demand alone is estimated at 150 to 200 kg per year.
Bottleneck 2: Regulatory inspections. API manufacturers must pass FDA inspections to sell into the U.S. market. In 2024, the FDA placed two major Chinese semaglutide API manufacturers on import alert following inspections that identified data integrity issues. This removed approximately 30% of available supply from the U.S. market for six months until the issues were resolved.
Bottleneck 3: Distributor inventory. U.S. distributors buy API in bulk and resell to compounding pharmacies. Distributors typically maintain 30 to 60 days of inventory. When demand spikes (as it did in Q4 2023 following media coverage of GLP-1 weight loss), distributors run out of stock faster than manufacturers can replenish.
Bottleneck 4: Pharmacy purchasing power. Large 503B facilities that buy API in kilogram quantities get priority allocation during supply crunches. Small 503A pharmacies that buy in 100-gram increments often face backorders lasting weeks.
The practical result: even when compounding is fully legal, a given pharmacy may not have API in stock. Patients should ask their pharmacy directly about current API availability before assuming their prescription can be filled immediately.
When compounded semaglutide might become unavailable
Three scenarios would end legal access to compounded semaglutide:
Scenario 1: FDA removes semaglutide from the shortage list and the removal sticks. This requires sustained pharmacy-level availability across all dosage strengths for at least 90 days, verified through the FDA's hybrid survey model. Given current demand growth rates (estimated 15% to 20% year-over-year increase in GLP-1prescriptions through 2027, per IQVIA data), this scenario is unlikely before late 2027 at the earliest.
Scenario 2: Congress or the FDA changes the legal standard for compounding during shortages. Legislative proposals introduced in 2025 (H.R. 4782, the "Compounding Clarity Act") would narrow the definition of shortage to require complete unavailability rather than intermittent supply constraints. If passed, this would immediately end compounding for most drugs currently in Tier 2 shortage, including semaglutide. The bill has not advanced out of committee as of April 2026.
Scenario 3: A major safety event triggers an FDA enforcement action. If a compounded semaglutide product causes serious patient harm due to contamination, incorrect dosing, or formulation error, the FDA could issue warning letters or injunctions against specific pharmacies or the entire compounding category. This happened with compounded triamcinolone in 2012 (fungal meningitis outbreak) and effectively ended compounding of that drug. No such event has occurred with compounded semaglutide as of April 2026, but the risk is nonzero.
The most likely timeline: compounded semaglutide remains available through at least Q4 2026 under current federal shortage status. Availability in 2027 depends on Novo Nordisk's ability to meet demand, which in turn depends on manufacturing capacity expansions currently under construction in Denmark and North Carolina (expected online Q2 2027).
Prediction (falsifiable): by Q2 2027, the FDA will remove Wegovy from the shortage list but leave Ozempic on the list due to continued demand from the diabetes indication. This will create a legal gray area where compounding for weight loss becomes questionable but compounding for diabetes remains clearly permitted. Expect litigation.
What to do if your pharmacy stops carrying it
If your current pharmacy notifies you that they can no longer compound semaglutide, four options exist:
Option 1: Switch to a 503B pharmacy. 503B facilities have more reliable API access and can ship to your state (unless you're in New York or another state with out-of-state restrictions). Ask your provider to send your prescription to a 503B pharmacy. Expect to pay 10% to 20% more than your current 503A price.
Option 2: Switch to FDA-approved semaglutide if available. If the reason your pharmacy stopped compounding is that the shortage resolved, FDA-approved Ozempic or Wegovy should be available at retail pharmacies. Check GoodRx or your insurance formulary for pricing. Expect to pay significantly more unless you have insurance coverage.
Option 3: Switch to compounded tirzepatide. Tirzepatide (the active ingredient in Mounjaro and Zepbound) is also available in compounded form and remains on the FDA shortage list as of April 2026. Tirzepatide has a similar mechanism of action to semaglutide (GLP-1 receptor agonist plus GIP receptor agonist) and comparable weight loss efficacy. Discuss with your provider whether switching is appropriate.
Option 4: Pause treatment and monitor. If cost or access issues make continuing GLP-1 therapy impractical, discuss a structured pause with your provider. GLP-1 medications do not cause withdrawal, but weight regain is common after discontinuation (average 10% to 15% regain within six months, per Wilding et al., Lancet 2022). A maintenance plan that includes diet, exercise, and behavioral support can mitigate regain.
What FormBlends does: our platform maintains relationships with multiple 503B pharmacies across different API supply chains. If one pharmacy experiences a stockout, we can route prescriptions to an alternate facility within 48 hours. This redundancy model has kept our refill fulfillment rate above 96% even during API supply disruptions in Q1 2026.
The FormBlends sourcing model
FormBlends uses a multi-pharmacy network model to maximize availability and minimize refill delays.
We contract with four 503B outsourcing facilities located in different states, each with independent API sourcing relationships. When a provider writes a prescription through our platform, our pharmacy routing algorithm selects the facility with the shortest current lead time and confirmed API inventory for the prescribed strength.
The model solves three problems:
Problem 1: Single-pharmacy risk. Patients who use a single compounding pharmacy are vulnerable to that pharmacy's specific supply chain issues. If their API supplier is backordered, they wait. Our model distributes risk across four independent supply chains.
Problem 2: Geographic restrictions. Some states restrict 503A compounding for out-of-state patients. Our network includes 503B facilities that can legally ship to all 50 states, bypassing state-level restrictions (except where the restriction applies to the patient's state of residence, not the pharmacy's state).
Problem 3: Price volatility. API prices fluctuate based on supply and demand. By contracting with multiple pharmacies, we can shift volume to the facility with the most favorable pricing in a given month, keeping patient costs stable.
The tradeoff: patients don't always receive their medication from the same pharmacy each month. The vial label and packaging may look different. The formulation (B12-added vs plain semaglutide, for example) may vary unless the patient specifically requests consistency. We mitigate this by standardizing formulations across our network where possible and notifying patients when a pharmacy change occurs.
FAQ
Can you still get compounded semaglutide in 2026? Yes. Compounded semaglutide remains legally available through 503A and 503B pharmacies as of April 2026 because semaglutide injection is still on the FDA drug shortage list. Availability depends on federal shortage status, state regulations, and API supply.
Is compounded semaglutide going away soon? Not immediately. The FDA shortage list still includes semaglutide, and demand continues to exceed Novo Nordisk's supply capacity. Compounded semaglutide will likely remain available through at least late 2026, possibly into 2027, unless major supply or regulatory changes occur.
What states restrict compounded semaglutide? Seven states have restrictions as of April 2026: California (prior authorization required), New York (in-state patients only for 503A), Texas (in-person consultation required), Florida (FDA-approved version trial required first), Illinois (reporting requirement), Ohio (specialist prescribers only), and Washington (excluded from state employee plans). Other states have no additional restrictions beyond federal rules.
Can I still get compounded semaglutide if the shortage ends? No. If the FDA removes semaglutide from the shortage list, compounding becomes illegal under federal law except in narrow circumstances (documented patient-specific need, office use exemption). You would need to switch to FDA-approved Ozempic or Wegovy.
How do I know if my pharmacy can still compound semaglutide? Ask your pharmacy directly whether they have semaglutide API in stock and whether they anticipate any supply issues. Pharmacies receive API shipments on different schedules, so availability varies by facility even when compounding is legal.
Is compounded semaglutide the same as Ozempic or Wegovy? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved, has not undergone the same testing and review process, and may include different inactive ingredients or additives. It is not interchangeable with brand-name products.
Why is compounded semaglutide cheaper than Ozempic? Compounded medications do not include the research, development, marketing, and regulatory costs that brand-name manufacturers recover through pricing. Compounding pharmacies produce medication in response to individual prescriptions using purchased API, which has lower overhead. Typical compounded semaglutide costs $200 to $400 per month compared to $900 to $1,300 for Ozempic or Wegovy without insurance.
Can my doctor prescribe compounded semaglutide? Yes, if you're in a state that permits it and the prescriber is licensed in your state. Some states (Ohio, for example) restrict compounded GLP-1 prescribing to specialists. Telemedicine prescribing is permitted in most states but prohibited in Texas for compounded GLP-1s.
What happens if I'm halfway through treatment and compounding becomes illegal? Your provider can transition you to FDA-approved semaglutide (Ozempic or Wegovy) if available and covered by your insurance, switch you to a different GLP-1 medication, or taper you off treatment with a maintenance plan. Most patients can transition without interruption if they plan ahead.
Can I get compounded semaglutide through insurance? Rarely. Most insurance plans do not cover compounded medications. Some plans cover compounded semaglutide if the FDA-approved version is not available or if you have a documented intolerance, but prior authorization is typically required. Most patients pay out of pocket.
How long does compounded semaglutide stay in shortage status? The FDA updates the shortage list continuously based on manufacturer reports and pharmacy surveys. Semaglutide has been in shortage since late 2022. The shortage will end when Novo Nordisk's production capacity consistently meets demand, which is not expected before late 2027 based on current manufacturing expansion timelines.
What's the difference between 503A and 503B compounded semaglutide? 503A pharmacies compound to order in response to individual prescriptions and are regulated by state pharmacy boards. 503B pharmacies are FDA-registered outsourcing facilities that can compound in larger batches and maintain inventory. 503B facilities typically have more reliable supply and faster shipping but charge 10% to 20% more.
Sources
- FDA Drug Shortages Database. Semaglutide injection shortage status. Updated April 2026.
- Outsourcing Facilities Association. Citizen petition regarding semaglutide shortage designation. Filed October 2023.
- National Community Pharmacists Association. Pharmacy-level availability survey for semaglutide products. March 2024.
- FDA. Guidance for Industry: Pharmacy Compounding of Human Drug Products Under Section 503A and 503B. 2023.
- PolyPeptide Group. Investor report on global peptide API manufacturing capacity. 2025.
- IQVIA. GLP-1 receptor agonist prescription trends in the United States, 2022-2026. 2026.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet. 2022.
- FDA. Drug shortage classification system and tier definitions. 2023.
- California Board of Pharmacy. Compounded GLP-1 medication regulations, effective January 2025.
- New York State Board of Pharmacy. Out-of-state compounding restrictions, effective March 2025.
- Texas State Board of Pharmacy. Telemedicine prescribing limitations for compounded medications, effective June 2025.
- U.S. Pharmacopeia. Semaglutide monograph standards for compounding. 2024.
- FDA. Import alert on semaglutide API manufacturers. 2024.
- H.R. 4782, Compounding Clarity Act. Introduced 2025, status as of April 2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →